Completed PHASE2 INTERVENTIONAL 2-arm NCT00774072

Nasal Inhalation of Tobramycin in Patients With Cystic Fibrosis and Pseudomonas Aeruginosa Colonization

Nasal Inhalation of Tobramycin by the Pari Sinus Nebulizer in Patients With Cystic Fibrosis and Pseudomonas Aeruginosa Colonization in the Upper Airways

Sponsor: University of Jena

Conditions Cystic Fibrosis Pseudomonas Aeruginosa

Interventions Tobramycin (Gernebcin®)

Updated 5 times since 2017 Last updated: Dec 3, 2014 Started: Oct 31, 2008 Primary completion: Nov 30, 2010 Completion: Nov 30, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Cystic Fibrosis and Pseudomonas Aeruginosa and is currently completed. University of Jena leads this study, which shows 5 recorded versions since 2008 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Oct 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University of Jena

Data source: University of Jena

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Jena, Germany
• Tübingen, Germany